Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002755876 | SCV003016111 | benign | not provided | 2023-07-07 | criteria provided, single submitter | clinical testing | |
Ce |
RCV002755876 | SCV004011686 | likely benign | not provided | 2023-06-01 | criteria provided, single submitter | clinical testing | PHIP: BP4 |
Ambry Genetics | RCV003340535 | SCV004057791 | likely benign | Inborn genetic diseases | 2023-06-26 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Prevention |
RCV004736199 | SCV005353761 | uncertain significance | PHIP-related disorder | 2024-08-09 | no assertion criteria provided | clinical testing | The PHIP c.2786A>T variant is predicted to result in the amino acid substitution p.Glu929Val. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.016% of alleles in individuals of European (Non-Finnish) descent in gnomAD, which may be too frequent to be a primary cause of disease. Although we suspect that this variant may be benign, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |